Sarcopenia
Welcome,         Profile    Billing    Logout  
 46 Companies   12 Products   12 Products   17 Mechanisms of Action   835 Trials   24915 News 


«12...354355356357358359360361362363364...442443»
  • ||||||||||  [VIRTUAL] Measured versus Estimated Resting Metabolic Rate in Heart Failure With Preserved Ejection Fraction (OnDemand) -  Oct 10, 2020 - Abstract #AHA2020AHA_5176;    
    Estimations of resting metabolic rate in patients with HFpEF demonstrated a fixed bias towards overestimation when compared to measured RMR by metabolic cart. Given HFpEF populations are often obese and are counseled routinely on weight loss, understanding the implicit bias of equations estimating RMR is vital when providing nutritional and dietary counseling.
  • ||||||||||  Journal:  Sarcopenia in Cirrhosis: Fallout on Liver Transplantation. (Pubmed Central) -  Oct 9, 2020   
    Almost 50% of LT recipients had sarcopenia, who had a higher incidence of postoperative sepsis, neurological complications, longer ICU stay and ventilatory support. Low SMI, ACLF presentation, and intraoperative blood loss were the independent predictors of early mortality.
  • ||||||||||  Journal:  ROMANIAN TRANSLATION AND VALIDATION OF THE SARC-F QUESTIONNAIRE. (Pubmed Central) -  Oct 9, 2020   
    Using the more conservative diagnostic criteria the negative predictive value was: 85.4%, sufficient to rule out those not at risk of having sarcopenia and eliminate the need for further investigations. A valid Romanian Sarc-F questionnaire is now available to simply detect patients at risk/no risk of sarcopenia.
  • ||||||||||  Biomarker, Journal:  Circulating Biomarkers of Accelerated Sarcopenia in Respiratory Diseases. (Pubmed Central) -  Oct 8, 2020   
    We found a modest-to-significant increase in the plasma markers of inflammation, oxidative stress and muscle damage, which had varying degrees of correlations with Dkk-3, CAF22 and selected micro RNAs (miRs) in respiratory diseases. Taken together, our data show that plasma levels of Dkk-3, CAF22 and selected miRs can be useful tools to assess accelerated sarcopenia phenotype in the elderly with respiratory diseases.
  • ||||||||||  Review, Journal:  Nutrition and microRNAs: Novel Insights to Fight Sarcopenia. (Pubmed Central) -  Oct 8, 2020   
    Besides, we explored the role of nutrition as a possible way to counteract the loss of muscle mass and function associated with ageing, with special attention paid to nutrient-dependent miRNAs regulation. This review will provide important information to better understand sarcopenia and, thus, to facilitate research and therapeutic strategies to counteract the pathophysiological effect of ageing.
  • ||||||||||  [VIRTUAL] The impact of body composition on long‐term outcomes in patients with colorectal cancer () -  Oct 8, 2020 - Abstract #ESCP2020ESCP_225;    
    This review will provide important information to better understand sarcopenia and, thus, to facilitate research and therapeutic strategies to counteract the pathophysiological effect of ageing. Visceral obesity does not seem to affect long‐term outcomes of patients with CRC, while sarcopenia presents a negative prognostic impact on both OS and CRS.
  • ||||||||||  everolimus / Generic mfg.
    [VIRTUAL] Prognostic value of sarcopenia in metastatic renal cell carcinoma patients: A systematic review (On-Demand e-Poster Display) -  Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_1252;    
    However, other 2 studies found that there were no significant differences in chemotherapy toxicity between sarcopenic and non-sarcopenic patients treated with tyrosine kinase inhibitor and everolimus...Legal entity responsible for the study: The authors. Funding: Has not received any funding.
  • ||||||||||  everolimus / Generic mfg.
    [VIRTUAL] Prognostic value of sarcopenia in metastatic renal cell carcinoma patients: A systematic review (On-Demand e-Poster Display) -  Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_887;    
    However, other 2 studies found that there were no significant differences in chemotherapy toxicity between sarcopenic and non-sarcopenic patients treated with tyrosine kinase inhibitor and everolimus...There were 5 studies with good quality, 4 studies with moderate quality, and 1 study with poor quality. Further investigation is needed with better methods and outcome that focuses on chemotherapy toxicity and quality of life.
  • ||||||||||  everolimus / Generic mfg.
    [VIRTUAL] Prognostic value of sarcopenia in metastatic renal cell carcinoma patients: A systematic review (On-Demand e-Poster Display) -  Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_518;    
    However, other 2 studies found that there were no significant differences in chemotherapy toxicity between sarcopenic and non-sarcopenic patients treated with tyrosine kinase inhibitor and everolimus...There were 5 studies with good quality, 4 studies with moderate quality, and 1 study with poor quality. Further investigation is needed with better methods and outcome that focuses on chemotherapy toxicity and quality of life.